Downloads provided by UsageCounts
handle: 10261/42322
La enfermedad de Chagas afecta a unos 20 millones de personas en América Latina, con un alto grado de mortalidad y morbilidad. Los intensos flujos migratorios hacen actualmente de ésta una enfermedad de nuestro entorno. Hasta la fecha, el único crieterio de cura parasitaria es la ausencia de anticuerpos frente a extractos e proteínas totales o mezcla de antígenos de Trypanosoma cruzi, medida por ensayos serlógicos convencionales. Sin embargo, estos tests no resultan útiles para el seguimiento a corto y medio plazo tras el tratamiento.
P06-CTS-02242-PAI (Junta de Andalucía); RD06/0021/0014-ISCIII-RETIC (MICINN), España.
1 página. Resumen de la conferencia.
Peer reviewed
Benznidazol, Trypanosoma cruzi, Marcadores serológicos, Proteínas recombinantes, Pacientes chagásicos
Benznidazol, Trypanosoma cruzi, Marcadores serológicos, Proteínas recombinantes, Pacientes chagásicos
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
| views | 21 | |
| downloads | 21 |

Views provided by UsageCounts
Downloads provided by UsageCounts